Login / Signup
Zihong Chen
ORCID
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 3
Top Topics
Peritoneal Dialysis
Clinical Trial
Ejection Fraction
Small Cell Lung Cancer
Top Venues
Cancer medicine
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Yaxiong Zhang
,
Zihong Chen
,
Yu Liu
,
Liang Han
,
Wei Jiang
,
Qiming Wang
,
Jianhua Shi
,
Liqin Lu
,
Jianying Li
,
Mingjun Zhang
,
Yan Huang
,
Yunpeng Yang
,
Xue Hou
,
Li Zhang
,
Jing Li
,
Wenfeng Fang
,
Gang Chen
Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Cancer medicine
13 (7) (2024)
Yaxiong Zhang
,
Zihong Chen
,
Yu Liu
,
Liang Han
,
Wei Jiang
,
Qiming Wang
,
Jianhua Shi
,
Liqin Lu
,
Jianying Li
,
Mingjun Zhang
,
Yan Huang
,
Yunpeng Yang
,
Xue Hou
,
Li Zhang
,
Jing Li
,
Wenfeng Fang
,
Gang Chen
Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Cancer medicine
13 (7) (2024)
Yaxiong Zhang
,
Zihong Chen
,
Yu Liu
,
Liang Han
,
Wei Jiang
,
Qiming Wang
,
Jianhua Shi
,
Liqin Lu
,
Jianying Li
,
Mingjun Zhang
,
Yan Huang
,
Yunpeng Yang
,
Xue Hou
,
Li Zhang
,
Jing Li
,
Wenfeng Fang
,
Gang Chen
Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Cancer medicine
13 (7) (2024)